A Pilot Study of Centrifugal Leukocyte Apheresis for Corticosteroid-Resistant Active Ulcerative Colitis

Internal Medicine

Volumn 36, Issue 5, 1997, Pages 322-326

  Ayabe, Tokiyoshi ^a   Ashida, Toshifumi ^a   Taniguchi, Masato ^a   Nomura, Masafumi ^a   Einami, Katsuya ^a   Taruishi, Masaki ^a   Saitoh, Yusuke ^a   Santos, Severino B ^a   Ono, Minoru ^a   Shibata, Yoshimi ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Cell adhesion molecules; Corticosteroid resistance; Inflammatory bowel disease; Leukocytapheresis; VLA 4, L selectin

Indexed keywords

CORTICOSTEROID; HOMING RECEPTOR; INTEGRIN; L SELECTIN; PREDNISOLONE; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; BLOOD; CHILD; DRUG RESISTANCE; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PILOT STUDY; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; CHILD; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; L-SELECTIN; LEUKAPHERESIS; LEUKOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; RECEPTORS, LYMPHOCYTE HOMING;

EID: 0031135243     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.36.322     Document Type: Article

References (15)

1. Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 150: 2487, 1993.
2. Gross WL, Schmitt WH, Csernok E. ANCA and associated disease: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 91: 1, 1993.
3. Yang H, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 92: 1080, 1993.
4. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253, 1993.
5. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic entrocolitis. Cell 75: 263, 1993.
6. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filler, for inflammatory bowel disease. J Gastroenterol 30: 322, 1995.
7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82, 1989.
8. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quarterly J Med 120: 393, 1961.
9. Bicks RC, Groshart KW, Chandler RW. The treatment of severe chronically active Crohn's disease by T8 (suppressor cell) lymphocytapheresis. Gastroenterology 88: A1325, 1985.
10. Lerebours E, Bussel A, Modiglian R, et al. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 107: 357, 1994.
11. Chadwick VC. Lymphocyte apheresis in Crohn's disease. Gastroenterology 107: 579, 1994.
12. Toyoda H, Wang SJ, Yang H, et al. Distinct association of HLA class II genes with inflammatory bowel disease. Gastroenterology 104: 741, 1993.
13. 90mTc- HMPAO labeled leukocyte imaging in ulcerative colitis. Jpn J Nucl Med 33: 711, 1996 (Abstract in English).
14. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest 92: 372, 1993.
15. Taniguchi M, Ayabe T, Ashida T, et al. Soluble L-selectin as a new serological indicator for ulcerative colitis. Gastroenterology 110: A1025, 1996.